Skip to content

US · SWKHL · ASSET MANAGEMENT

SWK Holdings Corporation 9.00% Senior Notes due 2027 (SWKHL) intrinsic value and stock valuation

$25.21as of 2026-11-21 · Mkt cap 193.77M

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

SWK Holdings Corporation 9.00% Senior Notes due 2027 DCF and intrinsic value

InvestorsCraft values SWKHL with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from SWKHL’s statements →

SWK Holdings Corporation 9.00% Senior Notes due 2027 Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Financial Services · Asset Management Dallas, TX 75254 swkhold.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$40.8M+2.1% 5y CAGRd
20112025
Net income
-$-2.53M
20112025
Free cash flow
$26.8M+11.8% 5y CAGRd
20112025
Total equity
$235.1M-0.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$40.8M$45M$37.8M$41.5M$56.2M
Operating income$24M$11.6M$14.7M$9.97M$31M
Net income-$-2.53M$13.5M$15.9M$13.5M$25.9M
EPSd-$-208.06K$1.08M$1.25M$1.05M$2.02M
Operating cash flow$27.3M$23.1M$14.9M$8.2M$34.3M
Capital expenditure-$-510K-$-140K-$-500K-$-300K-$-1.08M
Free cash flow$26.8M$22.9M$14.4M$7.91M$33.2M
Total assets$272.4M$332.2M$334.3M$299.6M$282.7M
Total debt$32.1M$37.7M$43.1M$2.44M$10K
Net debt-$-10.65M$31.7M$38.6M-$-3.71M-$-42.85M
Total equity$235.1M$288.7M$280.3M$279.9M$267.2M
Cash and short-term investments$42.8M$5.93M$4.5M$6.16M$43.9M
Income statement
20252024202320222021
Revenue$40.8M$45M$37.8M$41.5M$56.2M
Cost of revenue$1.92M$2.2M$3.44M$6.95M$7.35M
Gross profit$38.8M$42.8M$34.3M$34.5M$48.8M
Research and development expenses$1.55M$2.2M$0.00$0.00$0.00
Selling, general and administrative expenses$14.8M$11.5M$11.2M$13M$13.6M
Other expenses-$-1.5M$17.5M$8.44M$11.6M$4.15M
Operating expenses$14.8M$31.2M$19.7M$24.6M$17.8M
Cost and expenses$16.7M$33.4M$23.1M$31.5M$25.1M
Interest income$38.4M$0.00$0.00$0.00$0.00
Interest expense$4.8M$4.68M$1.85M$340K$370K
Depreciation and amortization$180K$1.81M$2.91M$2.83M$4.31M
Ebitda$25.1M$24.9M$19.4M$12.7M$37.7M
Operating income$24M$11.6M$14.7M$9.97M$31M
Total other income/expenses, net-$-3.91M$6.79M-$-40K-$-480K$1.97M
Income before tax$20.1M$18.4M$14.6M$9.49M$33M
Income tax expense$22.7M$4.88M-$-1.27M-$-4M$7.08M
Net income-$-2.53M$13.5M$15.9M$13.5M$25.9M
Weighted average shares outstanding$12.2M$12.4M$12.7M$12.8M$12.8M
Weighted average diluted shares outstanding$12.2M$12.5M$12.7M$12.9M$12.8M
Balance sheet
20252024202320222021
Cash and short-term investments$42.8M$5.93M$4.5M$6.16M$43.9M
Net receivables$3.86M$5.79M$4.73M$3.09M$1.8M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$46.8M$20.3M$11.9M$10.4M$47.4M
Property, plant and equipment, net$0.00$50K$5.44M$5.84M$5.78M
Goodwill and intangible assets$0.00$0.00$6.49M$16.6M$18.4M
Long-term investments$180K$580K$50K$80K$3.61M
Total non-current assets$225.6M$312M$322.4M$289.3M$235.2M
Total assets$272.4M$332.2M$334.3M$299.6M$282.7M
Accounts payable$0.00$0.00$0.00$0.00$5.09M
Short-term debt$0.00$0.00$0.00$2.44M$10K
Deferred revenue$0.00$1.5M$0.00$0.00$0.00
Total current liabilities$4.97M$5.57M$3.94M$6.35M$5.09M
Long-term debt$32.1M$37.7M$43.1M$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$32.4M$38M$50M$13.4M$10.3M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$37.3M$43.6M$53.9M$19.7M$15.4M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-4.18B-$-4.13B-$-4.14B-$-4.15B-$-4.16B
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$235.1M$288.7M$280.3M$279.9M$267.2M
Total investments$180K$580K$50K$80K$4.64M
Total debt$32.1M$37.7M$43.1M$2.44M$10K
Net debt-$-10.65M$31.7M$38.6M-$-3.71M-$-42.85M
Cash flow statement
20252024202320222021
Net income-$-2.53M$13.5M$15.9M$13.5M$25.9M
Depreciation and amortization$180K$1.81M$2.91M$2.83M$4.06M
Stock-based compensation$1.18M$940K$510K$500K$1.16M
Change in working capital$7.03M$530K-$-970K-$-3.47M$480K
Accounts receivable$1.93M-$-1.06M-$-1.64M-$-1.29M$110K
Inventory$0.00$0.00-$-790K$0.00-$-110K
Accounts payable$1.59M-$-1.33M$400K-$-1.6M$2.16M
Net cash provided by operating activities$27.3M$23.1M$14.9M$8.2M$34.3M
Investments in property, plant and equipment-$-510K-$-140K-$-500K-$-300K-$-1.08M
Acquisitions, net$6.9M$0.00$0.00$0.00$0.00
Net cash used for investing activities$68.1M-$-10.13M-$-48.95M-$-43.55M$25.8M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-3.07M-$-6.01M-$-6.33M-$-1.14M-$-370K
Dividends paid-$-49.08M$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-58.51M-$-12.22M$33.1M-$-1.36M-$-20.2M
Net change in cash$36.8M$690K-$-920K-$-36.71M$39.9M
Cash at end of period$42.8M$5.93M$5.24M$6.16M$42.9M
Operating cash flow$27.3M$23.1M$14.9M$8.2M$34.3M
Capital expenditure-$-510K-$-140K-$-500K-$-300K-$-1.08M
Free cash flow$26.8M$22.9M$14.4M$7.91M$33.2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About SWK Holdings Corporation 9.00% Senior Notes due 2027

        SWK Holdings Corporation, established in Dallas, Texas, in 1996, is a specialized financial institution primarily focused on the healthcare sector. The company's activities are organized into two core divisions: Finance Receivables and Pharmaceutical Development. Through its Finance Receivables segment, SWK delivers tailored funding solutions to a broad range of entities within the life sciences industry. This client base includes firms in biotechnology, medical devices, medical diagnostics, animal health, and pharmaceuticals, as well as various institutions and individual innovators. Additionally, this division provides non-discretionary investment advisory services, overseeing separate accounts for institutional clients interested in life science investments. The Pharmaceutical Development division is involved in the full spectrum of drug creation, encompassing development, formulation, manufacturing, and intellectual property licensing, notably leveraging its proprietary Peptelligence platform. A central aim for this division is to out-license its internal pipeline of products, utilizing its distinct technological expertise to develop innovative treatments designed to enhance outcomes for patients and caregivers. The company was previously known as Kana Software, Inc., before officially rebranding as SWK Holdings Corporation in December 2009.

        CEO
        Jody. D Staggs
        Employees
        24
        Beta
        0.06

        Explore

        Frequently asked questions

        What is the intrinsic value of SWK Holdings Corporation 9.00% Senior Notes due 2027 (SWKHL)?

        SWK Holdings Corporation 9.00% Senior Notes due 2027 (SWKHL) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SWKHL undervalued?

        SWKHL trades at a price of $25.21 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.